Coherus Oncology Inc

CHRSNASDAQ · USD
0.51USD0.00 (-3.73%)
322

Coherus Oncology Inc (CHRS) Historical Volatility

CHRS's 30 day historical volatility is 132.75%, in the 99th percentile of readings over the past year. This is a high percentile, meaning Coherus Oncology Inc shares have swung far more than usual. CHRS's 30 day implied volatility sits at 511.96%, with an IV Rank of 98.02%, leaving IV 379.21 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.

Read more

Tracking CHRS historical volatility helps you see how much Coherus Oncology Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CHRS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CHRS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CHRS's 30 day historical volatility, or CHRS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CHRS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.

Historical Volatility

HV Percentile
99thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)132.75%

HV Percentile99th

Implied Volatility (30d)511.96%

IV Rank98.02%

IV Minus HV+379.21%

As of Nov 16, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 16, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →